Cell therapy with hiPSC-derived RPE cells and RPCs prevents visual function loss in a rat model of retinal degeneration

Photoreceptor loss is the principal cause of blindness in retinal degenerative diseases (RDDs). Whereas some therapies exist for early stages of RDDs, no effective treatment is currently available for later stages, and once photoreceptors are lost, the only option to rescue vision is cell transplant...

Descripción completa

Detalles Bibliográficos
Autores: Salas Torras, Anna|||0000-0002-8781-9611, Duarri, Anna|||0000-0003-4075-5478, Fontrodona Montals, Laura, Ramírez Mora, Diana|||0000-0002-8962-8974, Badia Pérez, Anna|||0000-0001-8254-1641, Isla-Magrané, Helena|||0000-0002-7203-3309, Ferreira-de-Souza, Barbara, Zapata, Miguel Angel|||0000-0002-0096-4569, Raya, Ángel|||0000-0003-2189-9775, García Arumí, José|||0000-0001-8827-1160
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:237951
Acceso en línea:https://ddd.uab.cat/record/237951
https://dx.doi.org/urn:doi:10.1016/j.omtm.2021.02.006
Access Level:acceso abierto
Palabra clave:Cell therapy
Human-induced pluripotent stem cell
Retinal pigment epithelium
Photoreceptors
Retina degeneration
RCS rat
Regenerative medicine
RPE
IPSC
Subretinal injection
Descripción
Sumario:Photoreceptor loss is the principal cause of blindness in retinal degenerative diseases (RDDs). Whereas some therapies exist for early stages of RDDs, no effective treatment is currently available for later stages, and once photoreceptors are lost, the only option to rescue vision is cell transplantation. With the use of the Royal College of Surgeons (RCS) rat model of retinal degeneration, we sought to determine whether combined transplantation of human-induced pluripotent stem cell (hiPSC)-derived retinal precursor cells (RPCs) and retinal pigment epithelial (RPE) cells was superior to RPE or RPC transplantation alone in preserving retinal from degeneration. hiPSC-derived RPCs and RPE cells expressing (GFP) were transplanted into the subretinal space of rats. In vivo monitoring showed that grafted cells survived 12 weeks in the subretinal space, and rats treated with RPE + RPC therapy exhibited better conservation of the outer nuclear layer (ONL) and visual response than RPE-treated or RPC-treated rats. Transplanted RPE cells integrated in the host RPE layer, whereas RPC mostly remained in the subretinal space, although a limited number of cells integrated in the ONL. In conclusion, the combined transplantation of hiPSC-derived RPE and RPCs is a potentially superior therapeutic approach to protect retina from degeneration in RDDs. In this article, Anna Duarri and colleagues aim to develop a novel cell-based therapeutic approach to preserve retinal structure and function in retinal degenerative diseases caused by dysfunctional retinal pigment epithelium (RPE). Giving to the eye support of healthy RPE together with healthy retinal cells protects the retina from degeneration.